Search results for bethlem

Investigating mutations that cause Bethlem myopathy and Ullrich congenital muscular dystrophy

It has been known for some time that mutations in the gene coding for collagen VI could cause BM or UCMD. Collagen VI is a protein that forms part of an important structural layer found on the outside of the muscle cells....

Could Cyclosporine A be used to treat Bethlem myopathy and Ullrich congenital muscular dystrophy?

Muscular Dystrophy Campaign funded research at Newcastle University has investigated whether the drug Cyclosporine A could be used to treat Bethlem myopathy and Ullrich congenital muscular dystrophy (CMD)....

Update on BIO-NMD: A research project looking into Duchenne, Becker, Ullrich and Bethlem muscular dystrophies

A project newsletter has just been published which gives an overview of the progress of BIO-NMD - an EU funded project searching for biomarkers in patients with Duchenne and Becker muscular dystrophies and collagen 6-related myopathies (which includes Ull...

Clinical trial being planned for congenital muscular dystrophy

A clinical trial to test a drug called omigapil in Ullrich congenital muscular dystrophy, Bethlem myopathy and merosin-deficient congenital muscular dystrophy (MDC1A) is being planned for 2012....

Introducing the Inspire Awards winners

We are delighted to introduce the 2016 Muscular Dystrophy UK Inspire Awards winners. The awards were held at our Scottish Conference on Saturday 22 October at the Golden Jubilee Hotel in Glasgow. Kirsten Oswald MP presented the awards....

New research reveals potential treatment for congenital muscular dystrophy

Swiss pharmaceutical company Santhera has shown that Omigapil, a drug originally developed for treatment of neurological disorders such as Parkinson's disease, can improve symptoms of a severe type of congenital muscular dystrophy called merosin-deficient...

Online psychology study underway

An online questionnaire study examining how psychological factors impact on quality of life and mood over time has been started by researchers based at Edinburgh University....

New treatment strategy for neuromuscular conditions

Mitochondrial damage is thought to be one of the mechanisms leading to muscle cell death in muscular dystrophy....

New collaboration to support omigapil clinical trial for congenital muscular dystrophy

Santhera Pharmaceuticals have announced a collaboration that will help to facilitate the smooth transition of omigapil from the laboratory through to the clinic....

News

Near you

Find support and services in your area:

Keep in touch